Dr. Michael Y. Wang, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 145
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
OH license 35.085994 · MO license 2007004464 -
Hematology & Oncology Physician
MO license 2007004464
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Cleveland, OH
- Akron General Medical Center Akron, OH
- Mercy Medical Center Canton, OH
- Union Hospital Dover, OH
- Alliance Community Hospital Alliance, OH
Medical groups
- Cleveland Clinic (7,090 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 145
- Services billed
- 367
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 125 | 87 |
| Established patient office or other outpatient visit, 20-29 minutes | 62 | 54 |
| New patient office or other outpatient visit, 45-59 minutes | 38 | 38 |
| Established patient office or other outpatient visit, 40-54 minutes | 36 | 35 |
| Administration of chemotherapy into vein, 1 hour or less | 18 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Belpre, OH | 47 |
| Tamoxifen Citrate Other prescribers in Belpre, OH | 41 |
| Anastrozole Other prescribers in Belpre, OH | 32 |
| Prednisone Other prescribers in Belpre, OH | 30 |
| Hydroxyurea Other prescribers in Belpre, OH | 29 |
| Abiraterone Acetate | 28 |
| Ondansetron Hcl Other prescribers in Belpre, OH | 22 |
| Inlyta (axitinib) | 20 |
| Dexamethasone Other prescribers in Belpre, OH | 19 |
| Eliquis (apixaban) Other prescribers in Belpre, OH | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $4,132,616 in research payments for these studies, mostly to the institutions running them.
- Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
AbbVie Inc. · Active, not recruiting · NCT03282396 - A Phase II Study of Acalabrutinib plus rituximab in previously untreated elderly patients with Mantle Cell Lymphoma
AstraZeneca Pharmaceuticals LP - Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
AbbVie Inc. · Active, not recruiting · NCT01880567
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.